LOS ANGELES, May 31, 2012 /PRNewswire/ --WestPark Capital, Inc., a Los Angeles based investment banking company, today announced it has signed a non-exclusive engagement agreement with Alliqua, Inc. During the term of the engagement, WestPark Capitol shall provide advice to the company regarding business and finance, private and public equity and debt financing, and the company's relations with its securities holders and provide introductions to investors.
About Alliqua, Inc.
Alliqua Inc. (OTCBB: ALQA.OB) ("Alliqua") is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.
AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bio-artificial liver system, known as HepaMate™.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
For additional information, please visit www.alliqua.com
About WestPark Capital
WestPark Capital, Inc
|SOURCE WestPark Capital, Inc.|
Copyright©2010 PR Newswire.
All rights reserved